JP2012509366A - 核酸送達系のための放出可能ポリマー脂質 - Google Patents

核酸送達系のための放出可能ポリマー脂質 Download PDF

Info

Publication number
JP2012509366A
JP2012509366A JP2011536581A JP2011536581A JP2012509366A JP 2012509366 A JP2012509366 A JP 2012509366A JP 2011536581 A JP2011536581 A JP 2011536581A JP 2011536581 A JP2011536581 A JP 2011536581A JP 2012509366 A JP2012509366 A JP 2012509366A
Authority
JP
Japan
Prior art keywords
substituted
compound
alkyl
group
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011536581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509366A5 (enExample
Inventor
ザオ，ホン
ヤン，ウェイリ
シー，リャンジュン
ウー，デシュン
Original Assignee
エンゾン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンゾン ファーマシューティカルズ，インコーポレーテッド filed Critical エンゾン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2012509366A publication Critical patent/JP2012509366A/ja
Publication of JP2012509366A5 publication Critical patent/JP2012509366A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/49—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2011536581A 2008-11-17 2009-11-17 核酸送達系のための放出可能ポリマー脂質 Withdrawn JP2012509366A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11537908P 2008-11-17 2008-11-17
US11537108P 2008-11-17 2008-11-17
US61/115,379 2008-11-17
US61/115,371 2008-11-17
PCT/US2009/064701 WO2010057150A1 (en) 2008-11-17 2009-11-17 Releasable polymeric lipids for nucleic acids delivery systems

Publications (2)

Publication Number Publication Date
JP2012509366A true JP2012509366A (ja) 2012-04-19
JP2012509366A5 JP2012509366A5 (enExample) 2013-01-10

Family

ID=42170403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536581A Withdrawn JP2012509366A (ja) 2008-11-17 2009-11-17 核酸送達系のための放出可能ポリマー脂質

Country Status (7)

Country Link
US (1) US20110305770A1 (enExample)
EP (1) EP2362728A1 (enExample)
JP (1) JP2012509366A (enExample)
CN (1) CN102231950A (enExample)
CA (1) CA2742838A1 (enExample)
TW (1) TW201023914A (enExample)
WO (1) WO2010057150A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509258A (ja) * 2008-11-17 2012-04-19 エンゾン ファーマシューティカルズ，インコーポレーテッド 核酸送達系のための分岐カチオン性脂質

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
EP2741778A1 (en) * 2011-08-12 2014-06-18 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
PL2581448T3 (pl) * 2011-10-13 2015-08-31 Association Inst De Myologie Tricyklo-tiofosforanowy DNA
WO2013086354A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
HUE060907T2 (hu) * 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
AU2016253972B2 (en) 2015-04-27 2020-01-02 Acuitas Therapeutics Inc. Nucleoside-modified RNA for inducing an adaptive immune response
PT3313829T (pt) 2015-06-29 2024-07-08 Acuitas Therapeutics Inc Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
RU2730871C1 (ru) * 2015-09-30 2020-08-26 Сионоги Энд Ко., Лтд. Производное нуклеиновой кислоты, обладающее иммуностимулирующей активностью
EP3357514B1 (en) 2015-09-30 2021-04-14 NOF Corporation Lipid derivative in which hydrophilic polymer is bound via cyclic benzylidene acetal linkers
US10940201B2 (en) 2015-09-30 2021-03-09 Shionogi & Co., Ltd. Nucleic acid derivative having immunostimulatory activity
HRP20230209T1 (hr) 2015-10-28 2023-04-14 Acuitas Therapeutics Inc. Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
CA3049991A1 (en) 2017-01-11 2018-07-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an immune response against zika virus
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
CN110799492B (zh) 2017-04-28 2023-06-27 爱康泰生治疗公司 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
CA3073020A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
EP4501322A3 (en) 2017-08-17 2025-04-16 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
US11141491B2 (en) * 2018-10-15 2021-10-12 National Yang Ming Chiao Tung University PH-sensitive lipid nanoparticles for encapsulation of anticancer drugs and microRNA and use thereof
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CN109251150B (zh) * 2018-11-02 2021-07-30 宁夏医科大学 一种2，3-二氨基丙酸甲酯的制备方法
PT3908568T (pt) 2019-01-11 2024-09-30 Acuitas Therapeutics Inc Lípidos para a administração de agentes ativos por nanopartículas lipídicas
ES3054438T3 (en) 2020-07-16 2026-02-03 Acuitas Therapeutics Inc Cationic lipids for use in lipid nanoparticles
KR102433981B1 (ko) * 2020-12-15 2022-08-19 대구가톨릭대학교산학협력단 HIF-1α 및 STAT5 전사인자를 억제하는 합성 디코이 올리고핵산 및 이를 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 약학적 조성물
CN114904003B (zh) * 2021-02-09 2023-09-29 广州立得生物医药科技有限公司 可电离的阳离子脂质类似物材料在作为核酸药物递送载体或转染试剂中的应用
KR20240013087A (ko) 2021-05-24 2024-01-30 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 화합물 및 지질 나노입자 조성물
US20240408031A1 (en) * 2021-09-28 2024-12-12 The Trustees Of The University Of Pennsylvania Compositions and methods for t cell targeted delivery of therapeutic agents
CA3255883A1 (en) * 2021-10-01 2023-04-06 The Trustees Of The University Of Pennsylvania LIPID NANOPARTICLE (LNP) COMPOSITIONS AND THEIR METHODS OF USE
WO2023107920A1 (en) * 2021-12-07 2023-06-15 The Trustees Of The University Of Pennsylvania Anisamide-containing lipids and compositions and methods of use thereof
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CN116549659B (zh) * 2022-01-27 2025-11-21 中山大学 阳离子脂质类似物在基因编辑核糖核蛋白复合物胞内递送中的应用
CN114699997B (zh) * 2022-03-28 2022-11-25 山东大学 一种具有高抗盐性的碱基@囊泡复合体及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010503708A (ja) * 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド 多官能性リンカーを含む標的化ポリマープロドラッグ
HUE040417T2 (hu) * 2007-05-04 2019-03-28 Marina Biotech Inc Aminosavlipidek és alkalmazásuk

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509258A (ja) * 2008-11-17 2012-04-19 エンゾン ファーマシューティカルズ，インコーポレーテッド 核酸送達系のための分岐カチオン性脂質

Also Published As

Publication number Publication date
CA2742838A1 (en) 2010-05-20
WO2010057150A1 (en) 2010-05-20
EP2362728A1 (en) 2011-09-07
TW201023914A (en) 2010-07-01
WO2010057150A8 (en) 2011-01-06
US20110305770A1 (en) 2011-12-15
CN102231950A (zh) 2011-11-02

Similar Documents

Publication Publication Date Title
JP2012509366A (ja) 核酸送達系のための放出可能ポリマー脂質
JP2012509272A (ja) 核酸送達系のための放出性カチオン脂質
JP2012509273A (ja) 核酸送達系のための放出可能融合性脂質
JP2012509258A (ja) 核酸送達系のための分岐カチオン性脂質
JP2011529912A (ja) 核酸送達システム用のナノ粒子組成物
JP5977394B2 (ja) 脂質に封入された干渉ｒｎａ
WO2018225871A1 (ja) カチオン性脂質としての化合物
CN119032086A (zh) 含硫化物的可电离脂质和包含该可电离脂质的脂质纳米颗粒
CN117658848A (zh) 递送治疗剂的脂质化合物及其应用
CN115745788A (zh) 一种可电离脂质化合物及其制备方法和应用
WO2025102261A1 (zh) 递送治疗剂的脂质化合物及其制备方法与应用
HK1123751B (en) Lipid encapsulated interfering rna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121113

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20131211

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131219